Consequently, lung cancer patients with high levels of this marker on DCs showed a stronger antitumor response, with CD1d expression positively correlated with patient survival, and its level decreasing with the advancement of cancer stages (I–IV). This evidence concerns the gene CD1D and lung carcinoma.